
Sousan Karimi, M.D.
Education
2000-2002 | 2000-2002 Harbor UCLA Medical Center, Division of Nephrology and Hypertension Torrance, CA Nephrology Fellowship Program |
1997-2000 | 1997-2000 University of California, Irvine-Department of Internal Medicine Irvine, CA |
1993-1997 | George Washington University School of Medicine Washington, D.C. |
1987-1992 | 1987-1992 University of California, Los Angeles- Department of Biochemistry Los Angeles, CA Bachelor of Science in Biochemistry, June 1992 |
1985-1987 | 1985-1987 Van Nuys High School |
Professional Certificate
Nephrology | American Board of Nephrology, 2002-2012 |
Internal Medicine | American Board of Internal Medicine, 2001-2011 |
Medical | California Medical License, 1994-2004 |
DEA | Controlled Substance Registration Certicate (DEA), 2000-2004 |
Honors and Awards
- UCIMC Internal Medicine Clinic Award, February 2000
- School of Medicine Honor Society, 1993-1995
- UCLA Department of Biochemistry Award, 1992
- UCLA Cum Laude, 1992
- UCLA Medical Center Volunteer Scholarship Award, 1991
- Occidental College Summer Research Fellowship Recipient, 1989
Skills And Procedures
- Renal Ultrasonography
- Renal Biopsy
- Quinton cathere placement
- Flexible Sigmoidoscopy
- Central line Placement
- Thoracentesis, Paracentesis, and Arthrocentesis
- Lumbar Puncture
Practice Affiliation
Private Practice since 2002 in group known as Tower Nephrology Medical Group.
Research Experience
- D-dimer levels are elevated in adult patients with nephrotic syndrome.
- S. Karimi, R. Sinow, P. Fu, S. Adler. Harbor UCLA Medical Center. Presented at ASN 2001, San Francisco
- Expression of Major Histocompatibility Antigen and Vascilar Adhesion Molecules on Human Cardiac Allografts Preserved in University of Wisconsin solution. UCLA Medical Center, Division of Pathology and Cardiovascular surgery, 1992-1993
- Metabolic alterations avvompanu ionic disturbances and cellular swelling during a hypoxic indult to the retina: an in vitro study. UCLA Medical Center, Division of Neurosurgery 1991
- Structural study of Concanavalin A Molecule. Occidental College, Department of Physical Chemistry 1989
Clinical Study Location
- Tower Nephrology Medical Group, 8635 W. 3RD ST #485W Los Angeles, CA 90048
- DaVita of Beverly Hills, 50 N. La Cienega blvd. #300 Beverly hills, CA 90211
- DaVita of Crescent Heights, 8151 Beverly blvd Los Angeles, CA 90048
Clinical Studies
2013 ICH Good Clinical Practice for Clinical Trial Sites (Certificates)
Sub-Investigator | 2014 | Ferumoxytol for Anemia of CDK Trial (FACT): A Phase IV, open Label, Multicenter Trial, with MRI Substudy, of Repeated Doses Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Definiency Anemia (IDA) in Chronic Kidney Disease (CDK) Patients on Hemodialysis |
Sub-Investigator | 2014 | A Multicenter Single-arm Extention Study to Describe the Long- term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis |
Sub-Investigator | 2013 | A randomized, Double-blind, Placebo-controlled, Phase 3 Study to assess the Efficacy and Safety of AMG 416 in the Treatment of Seconday Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis. |
Sub-Investigator | 2013 | ZS-003: “A Phase III multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia. |
Sub-Investigator | 2013 | Randomized, Double-blind, Parallel-group, Multicenter study to evaluate the efficacy and safety of HX575 Epoetin alfa cs. US licensed Epoetin alfa (Epogen/Procrit) in the treatment of anemia associated with chronic kidney disease. |
Sub-Investigator | 2013 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults With Type 2 Diabetes and Overt Nephropathy Study #B1261007-1137 |
Sub-Investigator | 2012 | A phase 2b, Prospective, Double- Blind, Placebo- Controlled, Multicenter to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedence, in Type 2 Diabetic Subjects with Nephropathy |
Sub-Investigator | 2011 | A Three-Period, 58-Week Safety and Effiancy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis |
Sub-Investigator | 2011 | Bardoxolone Methyl Evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (Beacon) |
Sub-Investigator | 2011 | A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study |
2010 GCP Certified by the National Cancer Institute
Sub-Investigator | 2010 | A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease. |
Sub-Investigator | 2010 | Study to evaluate the improved management of iPTH with paracalcitol- centered therapy vs. cinacalcet therapy with low-dose vitamin d in hemodialysis patients with secondary hyperparathyroidism. |
Sub-Investigator | 2009 | A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor. |
Sub-Investigator | 2008 | Phase 2, randomized, double-blind, placebo-controlle, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia. |
Sub-Investigator | 2007 | A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin |
Sub-Investigator | 2007 | Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic haemodialysis |
Sub-Investigator | 2007 | A Phase IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects treated with lanthanum Carbonate (Fosrenol ®) |
Sub-Investigator | 2007 | A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center Injections. |
Sub-Investigator | 2007 | Prospective, Open Label, Randomized multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis. |
Sub-Investigator | 2007 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease. |
Sub-Investigator | 2007 | A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once- Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease |
Principal Investigator | 2007 | An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency |
Sub-Investigator | 2006 | A randomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2diabetes mellitus and diabetic nephropathy. |
Sub-Investigator | 2006 | Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular Events. |
Sub-Investigator | 2006 | A Phase III Study if the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis. |
Sub-Investigator | 2005 | An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease. |
Sub-Investigator | 2004 | Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis. |
Sub-Investigator | 2004 | Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis. |
Sub-Investigator | 2003 | Phase 3 Cinacalcet open label to reach K/DOQI levels |
Sub-Investigator | 2003 | Phase 3 trial in treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on Cinacalce. |
Sub-Investigator | 2003 | Phase 4 Prospective, Randomized, double-blind, double-dummy, forced- titration, multicenter, parallel group, one year treatment trial to compare MICARDIS (telmisartan) 80 mg versus COZAAR (losartan) 100mg, in hypertensive type 2 diabetic patients with overt nephropathy (AMADEO Study) |
Sub-Investigator | 2003 | Phase 3 Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent When Two Different Vitamin D Regimens are used in Subjects with Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD). |
Sub-Investigator | 2002 | Phase 4 to evaluate subject preference for Aranesp administered administered once monthly, ie every 4 weeks (Q4W) or procrit administered once weekly (QW). |